To perform a pulse ox on a baby, the health care provider wraps a soft sensor around the infant's ... However, the first FDA-approved OTC pulse ox (the Masimo MightySat Medical) came out in ...

Note that the Masimo trade secret lawsuit against Apple is separate from both an ITC injunction preventing the sale of Apple ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

It was really about the O2 sensor patent infringement case Masimo brought against Apple. In theory, that’s a completely unrelated case. In practice, not so much. If you need a quick recap ...

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price target of ...

Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...

Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches infringe two of its design patents as part of a broader intellectual property ...

In this article, we are going to take a look at where Masimo Corporation (NASDAQ:MASI) stands against other most promising medical stocks. The healthcare sector depends on medical technology ...

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings ... continue to benefit from the relocation of our sensor manufacturing to Malaysia in combination with ...